


To provide long-term capital appreciation.
| Name | % Net Assets |
|---|---|
| Astrazeneca | 4.6% |
| GlaxoSmithKline | 4.5% |
| Smiths Group | 4.3% |
| Logica | 4.3% |
| Carnival | 4.2% |
| Imperial Tobacco Group | 4.1% |
| BT Group | 4.1% |
| Bunzl | 4.0% |
| Unilever | 4.0% |
| BG Group | 4.0% |
| Key | % Net Assets |
|---|---|
| 4.6% | |
| 4.5% | |
| 4.3% | |
| 4.3% | |
| 82.3% |
| Date | 18-Mar-2022 |
|---|---|
| NAV | 177.12p |
| Currency | GBP |
| Change | 2.51p |
| % | 1.44% |
| YTD change | 177.12p |
| YTD % | n/a |
| Fund Inception | 05/11/2001 |
|---|---|
| Fund Manager | Marvyn Douglas |
| TER | 1.53 (31-Jan-2012) |
| Minimum Investment | |
|---|---|
| Initial | £5000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | 5.00% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.20 |
You are here: research